GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Cyclically Adjusted PB Ratio

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Cyclically Adjusted PB Ratio : 2.24 (As of Jun. 08, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-08), Ligand Pharmaceuticals's current share price is $81.36. Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $36.30. Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.24.

The historical rank and industry rank for Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

LGND' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.46   Med: 4.94   Max: 563.39
Current: 2.24

During the past years, Ligand Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 563.39. The lowest was 1.46. And the median was 4.94.

LGND's Cyclically Adjusted PB Ratio is ranked worse than
57.34% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs LGND: 2.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ligand Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $44.997. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $36.30 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.82 3.44 4.00 2.23 2.06

Ligand Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.21 1.77 2.06 2.01

Competitive Comparison of Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=81.36/36.3
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ligand Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=44.997/131.7762*131.7762
=44.997

Current CPI (Mar. 2024) = 131.7762.

Ligand Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.088 100.560 4.047
201409 2.206 100.428 2.895
201412 1.344 99.070 1.788
201503 1.788 99.621 2.365
201506 3.481 100.684 4.556
201509 14.669 100.392 19.255
201512 13.881 99.792 18.330
201603 18.836 100.470 24.705
201606 18.794 101.688 24.355
201609 17.723 101.861 22.928
201612 17.736 101.863 22.944
201703 18.993 102.862 24.332
201706 19.450 103.349 24.800
201709 20.136 104.136 25.481
201712 19.795 104.011 25.079
201803 23.339 105.290 29.210
201806 29.382 106.317 36.418
201809 33.160 106.507 41.027
201812 27.012 105.998 33.581
201903 54.921 107.251 67.480
201906 53.711 108.070 65.493
201909 48.430 108.329 58.912
201912 45.606 108.420 55.431
202003 41.240 108.902 49.902
202006 43.246 108.767 52.394
202009 43.367 109.815 52.040
202012 44.125 109.897 52.910
202103 44.790 111.754 52.815
202106 47.165 114.631 54.219
202109 48.606 115.734 55.343
202112 48.975 117.630 54.865
202203 47.043 121.301 51.105
202206 47.528 125.017 50.098
202209 48.319 125.227 50.846
202212 35.248 125.222 37.093
202303 37.721 127.348 39.033
202306 38.318 128.729 39.225
202309 38.339 129.860 38.905
202312 39.924 129.419 40.651
202403 44.997 131.776 44.997

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ligand Pharmaceuticals  (NAS:LGND) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Headlines

From GuruFocus

Ligand to Report Fourth Quarter Financial Results on February 22

By Business Wire Business Wire 02-06-2023

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

By Business Wire Business Wire 04-24-2023